Is Berkshire Hathaway Stock a Better Buy Than an S&P 500 Index Fund?

The article argues Berkshire Hathaway may offer a more attractive long-term risk-reward profile than S&P 500 index funds, citing nearly $50 billion of expected annual net earnings from its operating businesses. The S&P 500 trades above 20x forward earnings, with expectations heavily reliant on continued AI-driven growth; Vanguard and Goldman Sachs project 6%-7% average annual S&P 500 returns over the next decade versus the historical 10%. Berkshire's $1.1 trillion size, however, limits its capacity for the outsized returns it historically generated.

Analysis

The actionable signal is not a directional call on BRK.A versus the index; it is a factor-exposure question. BRK.A is a hybrid of regulated utilities, insurance float, industrial/consumer operating earnings, and a concentrated public-equity book, so it should hold up better than SPY in a multiple-reset scenario but will not be immune to a broad earnings recession. Its relative appeal rises if long-duration megacap growth derates while nominal rates remain elevated, because insurance investment income and cash optionality offset some operating-cycle pressure.

The consensus risk is treating Berkshire as a pure defensive alternative to AI-heavy index exposure. Its equity portfolio and economically sensitive subsidiaries still leave meaningful beta to consumer demand, freight, housing-related activity, and credit conditions; a recession that drives lower rates and wider credit losses could reduce the expected advantage. Conversely, a continued AI-led melt-up leaves BRK.A structurally vulnerable to benchmark underperformance because its capital base limits the impact of incremental investments and it lacks direct participation in the highest-momentum segment.

Over the next 1-3 months, the relative trade depends on whether market leadership broadens and whether 10-year Treasury yields remain above roughly 4%. Over 6-18 months, the more important catalyst is deployment of excess liquidity into acquisitions, buybacks, or public equities; absent visible capital deployment, a quality/defensive premium can compress. The article provides no new earnings, valuation, or capital-allocation data, so this is a watch-item rather than a standalone catalyst-driven trade.

Key Decisions for Investors

• Use BRK.B as a partial hedge for concentrated NVDA/AI exposure rather than a replacement for broad equity beta: pair long BRK.B / short an equal-beta sleeve of QQQ or SMH over a 3-6 month horizon if the 10-year yield stays above 4% and megacap earnings revisions flatten.
• Do not chase BRK.A on defensive rhetoric alone. Add only after confirming relative-strength improvement versus SPY and evidence of capital deployment; invalidate the relative-long thesis if BRK.B/SPY breaks below its prior 3-month range while EPS revisions turn negative.
• Maintain NVDA exposure only where AI revenue revisions continue to exceed valuation expansion. A sustained deceleration in hyperscaler capex guidance would favor rotating a portion of AI-beta into BRK.B, but the article itself does not establish such a deceleration.
• Watch GS as a second-order beneficiary if capital-markets activity and M&A accelerate, but avoid pairing it directly with BRK.A: GS is more cyclical and fee-market sensitive, whereas BRK's advantage is balance-sheet flexibility. Initiate only following confirmed improvement in advisory/backlog commentary.